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LDL, long established as the major plasma particle in the
transport of lipids, is considered the chief causative agent in
cardiovascular diseases. LDL particles have been the subject
of extensive study (1–6) that focused on commonly recognized properties of apo B100 as a lipid vector. A few “out-ofthe-box” studies in 1980s and early 1990s suggested that apo
B100 is involved in signal transduction pathways (7, 8), including regulation of immune response (9, 10). At present,
numerous studies support a role for LDL in signaling (11–
15). The function of LDL as a transporter of viral materials,
including nucleic acids, in the plasma was documented
(16–23); however, an explanation for this function at the
molecular level has yet to be provided.
Low density particles composed of lipid, apo B100, RNA,
and core protein of hepatitis C virus (hcv), termed lipoviro-particles, were reported in the plasmas of individuals
infected with hcv (17, 19, 21). These particles continue to
be studied as a source of persistent, chronic infection. In
addition, several reports have suggested that the hcv and
other Flaviviridae viruses may negotiate cell entry via the
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Abstract LDL mediates transfection with plasmid DNA in
a variety of cell types in vitro and in several tissues in vivo in
the rat. The transfection capacity of LDL is based on apo
B100, as arginine/lysine clusters, suggestive of nucleic acidbinding domains and nuclear localization signal sequences,
are present throughout the molecule. Apo E may also contribute to this capacity because of its similarity to the Dengue virus capsid proteins and its ability to bind DNA.
Synthetic peptides representing two apo B100 regions with
prominent Arg/Lys clusters were shown to bind DNA. Re0014
0160
gion 1 ( Lys-Ser ) shares sequence motifs present in
DNA binding domains of Interferon Regulatory Factors
and Flaviviridae capsid/core proteins. It also contains a
close analog of the B/E receptor ligand of apo E. Region 1
0014
0054
0055
peptides, B1-1 ( Lys-Glu ) and B1-2 ( Leu-Ala0096), mediate transfection of HeLa cells but are cytotoxic. Region 2
3313
3431
( Asp-Thr ), containing the known B/E receptor ligand,
shares analog motifs with the human herpesvirus 5 immediate-early transcriptional regulator (UL122) and Flaviviridae
3313
3355
NS3 helicases. Region 2 peptides, B2-1 ( Asp-Glu ),
3356
3431
and B2-2 ( Gly-Thr ) are ineffective in cell transfection
and are noncytotoxic. These results confirm the role of
LDL as a natural transfection vector in vivo, a capacity imparted by the apo B100, and suggest a basis for Flaviviridae
cell entry.—Guevara, J., Jr., N. Prashad, B. Ermolinksy, J. W.
Gaubatz, D. Kang, A. E. Schwarzbach, D. S. Loose, and N. V.
Guevara. Apo B100 similarities to viral proteins suggest basis for LDL-DNA binding and transfection capacity. J. Lipid
Res. 2010. 51: 1704–1718.

METHODS
Chemicals
All chemicals were of highest quality available. Water of 18.2
M⍀·cm resistivity was used throughout these studies. Tap water
was passed through a mixed-resin filter, distilled, and filtered using a Barnstead E-pure system. Molecular biology grade Agarose
was purchased from Fisher Scientific, Inc. PBS was obtained from
MediaTech, Inc., Herndon VA, or other chemical suppliers. Trisacetate (TA) buffer, DNA sequence grade, was obtained from
TECNOVA, Inc. Nucleic acid sample loading buffer was from
TM
Bio-Rad, Inc. BOBO1 -iodide (B-3582) and Cell Tracker™ CMTM
DiI (C-7001) fluorescence dyes, and Lipofectin were purchased
from Invitrogen, Inc. Synthetic peptides, of 95% or greater purity
by HPLC analysis, were purchased from GenScript, Corp.. Plasmid vectors, pCMV ␤-Gal, pEGFP-N1, and pEGFP-N2, were from
®
ClonTech, Inc. Plasmids, phMGFP, pGL2-Control, pCMVTNT ,
and restriction enzymes StuI and HindIII were obtained from
Promega, Inc. Cell culture media, DMEM, and HyQ-RPMI 1640
were obtained from MediaTech, Inc. and Thermo Fisher Scientific, Inc. Transfection Reagent 1, DOTAP: DOPE (1:1) was purchased from Avanti Polar Lipids, Inc. QIAamp DNA Mini kit was
obtained from QIAGEN, Inc. PCR reagents were obtained from
Roche Biochemicals, Inc. DNA Molecular Weight standards were
purchased from Roche Applied Science, Inc.

Isolation of plasma lipoproteins
Human. Highly purified preparations of human plasma LDL
were obtained from Invitrogen, Inc. and Athens Research and
Technology, Athens, GA. LDL was also isolated from human
plasma by sequential ultracentrifugation in NaBr solutions yielding the 1.019–1.05 g/ml density range of LDL fraction (6). Single
donor plasma with sodium EDTA added at time of collection was
obtained from Innovative Research. Typically, purified preparations of LDL were dialyzed in PBS containing 10 mM MgCl2. LDL
was than evaluated for purity using SDS-PAGE, and tested for
DNA binding capacity using electrophoretic mobility shift assay
(EMSA). Once DNA binding capacity of the LDL preparation
was confirmed, it was frozen drop-wise in liquid nitrogen and
stored in aliquots of about 200 µL in liquid nitrogen until needed.
Highly purified, delipidated apo E was purchased from Athens
Research and Technology, Inc.
Rats. Female Sprague-Dawley rats, 8–10 weeks old, were obtained from Harland Laboratories, Inc. Animals were housed in
the National Institutes of Health-accredited facilities in the University of Texas Health Science Center and Baylor College of
Medicine. All animals were treated in accordance with the Guide
for the Care and Use of Laboratory Animals published by the
U.S. National Institutes of Health (NIH publication no. 85-23,
revised in 1996). All animal protocols were approved by the Animal Welfare Committees at the University of Texas Health Science and Baylor College of Medicine.
Rat plasma was used to purify LDL. To obtain blood, animals
were first sedated using inhalation anesthetic metaphane. This
was followed by an injection of a combination anesthetic containing ketamine (42.8 mg/ml), xylazine (8.6 mg/ml), and acepromazine (1.4 mg/ml) in PBS. Blood was then collected by heart
puncture using a 5 ml syringe containing 50 µl of 100 mM EDTA.
Approximately 4–5 ml of blood was collected per animal. Samples were pooled and centrifuged at 400 rpm for 20 min. LDL
was isolated using equilibrium ultracentrifugation in preformed
gradient of KBr. Collected plasma, 9–10 ml from six rats, was diluted to 12 ml with saline, then the density of the sample was adjusted to 1.21 g/ml with KBr. Plasma was transferred to centrifuge
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LDL B/E receptor (24, 25). These observations suggest
possible links between LDL and viruses. Flaviviridae are
single-stranded RNA viruses with a genome that encodes
three structural proteins (capsid/core C protein, precursor membrane protein, and an envelope E protein) and
seven nonstructural proteins (NS1, NS2A, NS2B, NS3,
NS4A, NS4B, and NS5) (26). The genome is encapsulated
in a sphere that includes multiple copies of the capsid/
core protein. It is therefore possible that an analog sequence of the B/E receptor ligand (27, 28) is present in
the structural proteins of these viruses.
In previous reports, we showed that human LDL binds
DNA and RNA in vitro (18, 20) and that highly purified LDL
can be used to transport and deliver plasmid DNA to the cell
nucleus. We surmised that the capacity of LDL and VLDL to
bind nucleic acids is likely based on the presence of regions
in the apo B100 molecule that display sequence similarities
to known nucleic acid-binding domains (29). Based on the
location of arginine and lysine clusters and other motifs, five
potential DNA binding domains, 11 potential KH domains
of the heterogeneous nuclear ribonucleoprotein K (30,
31), and numerous bipartite nuclear localization signal sequences (NLS) were identified in the apo B100 primary
structure (18, 20). One candidate DNA-binding region is
contained in the first 100 N-terminal residues of the apo
B100. Several sequence motifs also present in the DNA-binding domains of interferon regulatory factors (29), the interferon regulatory factor (irf-s), are located in this region.
In this report, we explore the hypothesis that apo B100
and apo E have structural and functional similarities to
viral DNA-binding proteins. We focus on two candidate
nucleic acid-binding regions: N-terminus of apo B100, res0014
Lys-Ala0096 (Region 1) and the section encompassidues
ing the known B/E-receptor ligand of apo B100, residues
3313
Asp-Thr3431 (Region 2) (32,33). Sequences of these regions are compared with viral nucleic acid-binding proteins, the capsid/core proteins. The apo B100 Region 2
sequence is compared with the NS3 proteins of the Flaviviridae viruses [Dengue (dng), West Nile (wnlv), yellow fever (ylfv), and hepatitis C] (34, 35) and to UL122 protein
from human cytomegalovirus (HCMV) (36). In addition,
we expand our comparison of Region 1 to human irf proteins. Primary structure similarities strongly support these
two regions of the apo B100 molecule as nucleic acidbinding domains in apo B100. We also analyze similarities
151
between the receptor ligand region of apo E (Leu 278
Arg ) and dng capsid proteins and demonstrate DNAbinding capacity of purified apo E. Our hypothesis compels
us to consider that LDL and LDL-related particles, intermediate and very low density particles, are involved in
transporting nucleic acids, and this capacity is imparted by
specific regions of the apo B100 as well as apo E.
Here we present additional evidence that LDL and
VLDL have the capacity to bind DNA. Further, LDL can be
used to transfect a variety of cell types in vitro and in vivo.
Based on the results of experimental studies utilizing synthetic peptides from Regions 1 and 2 of apo B100, we conclude that this capacity is mediated by elements in the apo
B100 primary structure similar to viral proteins.

tubes of SW 40 Ti swinging bucket rotor (Beckman), 4 ml per
tube, overlaid with KBr solutions of the following densities: 1.063
g/ml (3.0 ml), 1.02 g/ml (3.0 ml), and 1.006 g/ml (2.5 ml). Samples were next centrifuged at 39,000 rpm for 60 h at 4°C. Seven
fractions were collected from each tube, starting from the top of
the centrifuge tube, and similar fractions from different centrifuge tubes were pooled then dialyzed against PBS. Protein concentration was routinely determined using modified Lowry
method (18), and SDS-PAGE (2–12%) was performed. LDL fraction was identified by presence of apo B100 band.

EMSA

Cells
All cell types used in these studies were obtained from the
American Type Culture Collection Organization. Cells were kept
in liquid nitrogen until needed and then grown according to
American Type Culture Collection protocols.
Several cell types, NIH/3T3 (mouse embryonic fibroblast cell
line, CRL-1658™), CHO (chinese hamster ovary, CCL-61™),
MCF7 (human breast adenocarcinoma cell line, HTB-22™), Hep
G2 (human hepatocyte carcinoma cells, HB-8065™), and HeLa
(human cervix epithelial adenocarcinoma cell line, CCL-2™),
were used for LDL- and apo B100 synthetic peptide-mediated
transfection. Cells were grown and maintained in media as
follows: HeLa, Hep G2, MCF7, and NIH/3T3 cell types were
in DMEM supplemented with 10% FBS, 100 units penicillin
G-sodium, 100 units/ml streptomycin sulfate, and 250 ng/ml amphotericin B. CHO cells were in RPMI-1640 containing 10% FBS,
L-glutamine, and 100 units penicillin G-sodium, 100 units/ml
streptomycin sulfate, and 250 ng/ml amphotericin B. Cells were
maintained at 37°C in an atmosphere of 5% CO2 in a humidified
incubator. Typically, cells were grown in culture plates (with or
without glass cover slip in wells) to 60–70% confluence (20).
Prior to transfection, the medium was removed, and cells were
washed thrice with PBS. Cells were then incubated for a minimum of 2 h but not more than 4 h in FBS-free medium.
Dual label experiments were conducted using Hep G2 cells.
The cells were grown overnight as described above on FBS-coated
cover slips to enhance attachment. Cells were next washed with
PBS and incubated in FBS-free medium for 4 h, then incubated
for 3 h in 200 µl of transfection solution containing FBS-free
DMEM, 10 mM MgCl2, and preformed complexes of BOBO-1labeled pCMV ␤-Gal plasmid DNA (3 µg), and either 15 µL of
CM-DiI-labeled LipofectinTM or 60 µg of CM-DiI-labeled LDL. The
cell-coated cover slips were then removed, washed in PBS, and
fixed in 4% paraformaldehyde for 10 min at 4°C. Each cover slip
was then inverted over a well of a hanging drop slides containing
PBS and viewed using an Olympus Model BH-2 fluorescent
microscope.
Similar methods were used to study LDL-mediated transfection of CHO, NIH3T3, and HeLa cells using BOBO-1-labeled
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Noncovalent labeling of plasmid DNA with BOBO-1
Labeling of DNA with BOBO-1™-iodide was accomplished according to the methods described by the vendor (Molecular
Probes dimeric cyanine nucleic acid stains) with minor modification. Briefly, 3 µl of 10 µM dye (1 mM stock solution diluted 1:100
with ethanol) was added to 10 g of DNA at a concentration of
0.5 g/l in PBS, and the solution was incubated at ambient
temperature for 1 h.

Labeling of LipofectinTM and LDL with CM-DiI
Labeling of LipofectinTM and LDL with Cell Tracker™ CM-DiI
was performed according to the methods described by the vendor
(Molecular Probes ). Transfection agents were labeled by adding
1 µl of 20 µg CM-DiI/ml in ethanol (stock solution) to 100 µL of
Lipofectin (undiluted reagent) or LDL (1.5 mg/ml by protein),
and the mixture was incubated for 1 h at ambient temperature.
Unreacted dye was removed using a Sephadex G-25 column.

Liposome preparation
Transfection Reagent 1 (10 mg, Avanti Polar Lipids, Inc.) was
dissolved in 2 ml of a sterile buffer solution of 0.9% NaCl, 5.0%
glucose, and 10% sucrose. The suspension was placed in a 37°C
water bath for 10 min and vortexed to disperse the opaque lipid
vesicles. Small unilamellar vesicles (SUV) were then formed by
sonicating the mix for about 3 min. The transparent SUV mix
was concentrated to approximately 11 mg/ml using an Amicon/
Microcon filter concentrator with a YM-3 membrane (Sigma,
Inc.). The solution was then sterilized through a 0.22 micron filter (Millipore, Inc.).

Transfection solutions
All LDL preparations used in this study were shown to bind
DNA in EMSA prior to cell transfection experiments. Plasmids
pCMV ␤-Gal, pEGFP-N1, pEGFP-N2, phMGFP, pGL2-Control,
and pCMVTNT® bound LDL in a similar manner.

LDL. For cell transfection, purified LDL was added to the
microfuge tube containing DNA and PBS with 10 mM MgCl2.
The mixtures were then incubated at 37°C for 30 min before use.
Typically, 20–40 µg of LDL protein was complexed with 1.0 µg
DNA.

Downloaded from www.jlr.org by guest, on January 22, 2020

An aliquot of plasmid DNA digested using restriction enzymes
was placed at the bottom of a microfuge tube; next, a buffer solution containing 25 mM TA, pH 7.6, and 10 mM MgCl2 was added.
An aliquot of purified lipoprotein (LDL, VLDL, apo E) or synthetic peptides was then added; the cocktail was stirred gently for
less than 5 s and incubated for 30 min at 37°C. Sample loading
buffer (Bio-Rad) was then added at a 1:5 (v/v) ratio to the polypeptide-DNA mix. Next, each sample was mixed and subjected to
electrophoresis using 0.5–0.8% agarose gels in TA buffer at 100
V. Aliquots of nucleic acid, synthetic peptides, and lipoprotein
were each analyzed in separate lanes as controls. DNA bands
were visualized using ethidium bromide. Peptides and proteins
in lipoprotein particles were visualized using Coomassie brilliant
blue R-250 (CBB).

plasmid DNA. CHO and NIH3T3 cells were grown on cover slips
and transfected using LDL complexed to BOBO-1-pEGFP-N1
DNA as described above, except LDL was not labeled. The cover
slips were recovered at different periods and were inverted over
on well slides containing PBS without paraformaldehyde treatment. Cell images were obtained using a LUMAMTM EPI-Fluorescent microscope. Similarly, HeLa cells were grown in Costar®
multi-well, flat bottom polystyrene plates and transfected using
solutions containing LDL complexed to BOBO-1-pCMVTNT
DNA. Results of HeLa cell transfection were documented using a
Zeiss Axiovert 25 microscope.
Nonlabeled LDL complexed to the nonlabeled pEGFP-N1
plasmid was used to transfect HeLa, MCF 7, CHO, and NIH/3T3
cell types as described above, and green fluorescence protein
(GFP) expression was documented using a LUMAMTM fluorescence microscope with a GFP filter.
HeLa cells were used also to ascertain the transfection capacity
of two sets of synthetic peptides. Cells were grown as routine, preconditioned in FBS-free DMEM for 4 h, washed thrice with PBS,
and 400 µl PBS supplemented with 10 mM MgCl2, containing either the synthetic peptides or peptide/DNA complexes was
added. Cells were incubated at 37°C as described in Methods for
30 min, then washed, and Trypan Blue dye in PBS was added.

LipofectinTM. Ten microliters of reagent in 100 µl culture medium was combined with 100 µl culture medium containing 10
µg DNA. The solution was then stirred gently and incubated for
at least 30 min at room temperature.
Liposome. Transfection Reagent 1 was prepared as described
above. The SUV preparation was combined with plasmid DNA
(10:1) in TE buffer and incubated at ambient temperature for
5 min before use.
Synthetic peptides. Amino acid sequences of the peptides are
listed in Table 1 (Region 1) and Table 3 (Region 2). Peptides
were received in lyophilized form and 1 mg/ml solutions were
prepared in PBS/10 mM MgCl2 by vortexing. Solutions were frozen drop wise in liquid nitrogen and stored at ⫺80°C until use.
Aliquots were thawed and sterilized using a 0.2 micron filter immediately prior to use. In EMSA, plasmid DNA was mixed with 3,
6, and 12 µg of peptide individually or in a mixture representing
a region of apo B100. Peptides were first mixed in equal amounts
(v/v) and incubated at 37°C for 30 min. The peptide mix was
then added to the DNA in a microtube after which PBS/MgCl2
buffer was added and the cocktail was mixed by repeated drawing
into the pipette tip.

Two separate animal studies were conducted. In one study at
Baylor College of Medicine, 12 rats were used to determine GFP
expression in different tissues after human LDL- and rat LDLmediated transfection. Prior to transfection, both human LDL and
rat LDL were shown to bind DNA in a similar manner using EMSA
(data not shown). Animals were separated into three sets. Transfection cocktails were introduced via multiple ports, including
those typically associated with viral infections such as HIV and
HSV. Each animal was given an intravenous injection in the femoral vein and subcutaneously; also, inoculants were introduced into
the peritoneal cavity, applied into the pharynx, nasal cavity, and
rectum. Animals in Set 1 (control) were inoculated with linearized
pEGFP-N1 plasmid DNA in which the HCMV I.E. promoter sequence was interrupted by digestion with HindIII, 5 µg of DNA in
100 µL of PBS/10 mM MgCl2 per site. Set 2 animals were inoculated with a preformed complex of purified rat LDL and pEGFPN1 plasmid, linearized using Stu I. Set 3 animals were inoculated
using a cocktail mix containing human LDL and linearized pEGFPN1 plasmid (100 µg of LDL protein and 5 µg of DNA in 100 µL of
PBS/10 mM MgCl2 per site). One animal from each set was euthanized as described above (Isolation of Plasma Lipoproteins section) on days 2, 5, and 7; tissues were excised and immobilized in
O.C.T. compound and frozen using liquid nitrogen. The immobilized tissue samples were sectioned using a cryomicrotome. Sections (5–8 µm thick) were fixed for 30 min in 4% paraformaldehyde
and analyzed for expression of GFP by fluorescent microscopy.
Animals scheduled for day 9 study were spared, because GFP expression was not observed in tissues harvested on days 5 and 7.
In separate experiments performed at UTHSC, four animals
were transfected with either pGL2-Control alone or pGL2Control complexed to LDL, cationic liposome (Transfection Reagent 1), or to a mixture of LDL and liposome and distribution
of the luciferase gene in rat tissues was determined by PCR.
Rats were anesthetized with ketamine/xylazine (200 mg/10
mg per 1 kg animal weight injected intraperitoneally) and a small
incision was made through the skin of the inner thigh to expose
the femoral vein. Injection of plasmid DNA was made with a 30
gauge needle directly into the femoral vein. After the injection,
pressure was applied to the puncture to avoid leakage and was
continued until coagulation occurred. The skin incision was

Fluorescent microscopy
Microscopy of Hep G2 cells and animal frozen tissue sections
was performed using an Olympus model BH-2 fluorescence
microscope equipped with a Hamamatsu 3 CCD model C5810
camera. The LUMAMTM EPI-Fluorescence microscope (LOMO
America, Inc.) equipped with an Optronics MacroFire® 2.0 CCD
camera and the Zeiss Axiovert 25 microscope with the Optronics
MicroFire CCD camera were used to obtain all other cell images.
The following filter sets were used: a fluorescein (FITC/TRITC)
no. 51004V2 cube, a Chroma HQ-GFP NB 710 cube no. 41020
(Chroma Technology, Brattleboro, VT), and an Olympus dichroic DM500 (BP490) filter.

Image processing
Adobe Photoshop CS version 8 software and full-frame images
of the same field of view of equal size and dimensions were used to
create merged overlay images. Images obtained at emission spectrum of 505–515 nm were used as background, and bright light
images or red region images were overlaid at 50% transparency.

Sequence alignment
Selection of protein sequences was based on the association of
LDL/VLDL and Flaviviridae viruses (24, 25) in human plasma, observations regarding colocation of apo B100 and HCMV DNA in
arterial wall (37, 38), our previous reports on the similarity of apo
B100 to irf proteins, and on preferential binding of LDL to CMV
promoter-containing plasmids (20). The apo E LDL receptor ligand sequence spanning residues Leu151 to Arg278 was also included. All protein sequences were obtained from the National
Institutes of Health protein database and saved as simple text documents. The capsid protein sequences for dng versions 1–4, hcv,
wnlv, ylfv virus, bovine viral diarrhea virus, and NS3 helicase sequences were obtained from their respective polyprotein files in
the same database. Rather than identifying all clusters of grouprelated amino acids, we first focused our efforts on two types of
clusters. The letter symbols for amino acids arginine (R), lysine
(K), histidine (H), proline (P), cysteine (C), and glycine (G) were
highlighted in each protein sequence file to locate basic amino
acid clusters such as the apo E LDL receptor ligand “RKXRKR”,
and motifs common to nucleic acid binding domains as well as
structurally important motifs such as “PG” and “GXXG”. Se-
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Animal transfection experiments

closed with a wound clip. All animals were injected with mixtures
containing 200 µg of pGL2-Control plasmid DNA (Promega,
Inc.). The control animal, rat1, was injected DNA in Tris-EDTA
buffer. Test rat2 was injected with pGL2-Control complexed with
LDL (1:5) in 10 mM Tris (pH 7.5), 40 mM NaCl, 1 mM EDTA, 1
mM DTT, and 4% glycerol. Rat3 was injected with pGL2-Control
complexed with the liposome (1:10, as described above) and rat4
was with cocktail composed of pGL2-Control: LDL: liposome
(1:1:7). Animals were anesthetized with ketamine/xylazine and
decapitated 24 h after the transfection injections were administered. Tissue samples were collected from heart, lung, liver,
brain, kidney, and spleen, weighed, and immediately frozen in
liquid nitrogen. Liquid N2 was added to the sample (25 mg of
each tissue, except 10 mg of spleen was used) in a cold mortar
and ground to a fine powder using a chilled pestle. Tissues were
digested with Proteinase K for 24 h at 56°C; DNA was then
extracted from each tissue using the QIAamp DNA Mini kit
(QIAGEN, Inc.) as described in the QIAGEN Handbook of Protocols. Presence of the luciferase gene was confirmed via PCR
using reagents from Roche Biochemicals, Inc., and a primer set,
5′agcaactgcataaggctatg and 3′gttggtactagcaacgcact obtained from
Genosys Biotechnologies, Inc. Reactions were performed in a
Perkin Elmer DNA Thermal Cycler Model 480.

RESULTS
DNA-binding
Present studies expand data on the capacity of LDL
to bind HCMV promoter-containing plasmids and to
transfect cells in vitro (18, 20); also, the latter property is
newly demonstrated in vivo. In Fig. 1 (upper panel), DNAbinding capacity of human lipoproteins, VLDL, LDL, and
HDL, is illustrated. LDL samples from two donors are
shown (donor A, lanes 1–5, and B, lanes 6–10); both samples had similar mobility in CBB-stained gel (middle
panel) and bound the pCMV ␤-Gal plasmid in almost
identical fashion (upper panel). VLDL, although a larger
apo B100-containing particle, displays higher electrophoretic mobility compared with LDL due to differences in
both lipid and protein contents (6, 39). Results shown in
Fig. 1 (lanes 14-15, donor B only) indicate that VLDL
binds to plasmid DNA in a concentration-dependent manner. Further, the mobility pattern for VLDL in the EMSA
differs from the pattern seen for LDL. At lower VLDL concentrations, bound DNA is seen in a band of higher electrophoretic mobility (lanes 12–13); the shift toward lower
mobility region is observed at increased VLDL protein/
DNA ratio (lanes 14–15) in the upper panel. In separate
experiments, high purity, delipidated apo E was used to
determine whether it contributes to the VLDL/DNA binding. Apo E binding to plasmid DNA (Fig. 1, lower panel)
suggests that both apo B100 and apo E may determine the
observed EMSA pattern for these particles.
Only apo B100-containing lipoproteins bound DNA in
our studies. HDL, which lacks apo B100, did not influence
plasmid mobility, lanes 16–18. Protease-treated LDL lost
its capacity to bind DNA in EMSA (not shown). Hence,
apo B100 is essential for DNA binding to lipoproteins.
1708
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Fig. 1. EMSA of human lipoproteins binding to linearized pCMV
␤-Gal. Upper panel: Ethidium bromide-stained gel, 0.75% agarose
in TA buffer, pH 7.6. Lanes 1–10: LDL binding to 1.0 µg of pCMV
␤-Gal linearized using HindIII. Lanes 1–5, LDL from donor A, 2.5,
5, 10, 20, and 30 µg by protein, respectively; lanes 6–10, LDL from
donor B, same protein amount as in lanes 1–5. Lanes 11–15: VLDL
(from donor B) binding to same plasmid DNA; 5, 10, 20, 30, and 60
µg of VLDL protein, respectively. Binding of LDL and VLDL to
DNA is evident by formation of lower-mobility band and decrease
in the amount of free plasmid as the concentration of lipoproteins
increases. HDL from donor B did not bind to the plasmid at
amounts of 10, 20, and 40 µg of HDL protein (lanes 16–18). Plasmid DNA alone is shown in lane 19. Middle panel: The same gel
stained with CBB dye. Bottom panel: Ethidium bromide-stained
0.8% agarose gel is shown in the left image. Lane 1: DNA ladder;
lane 2: 0.8 µg phMGFP plasmid; lanes 3–6: binding to the same
amount of plasmid by 1.8, 3.6, 5.4, and 7.6 µg, respectively, of >95%
pure, delipidated apo E; lane 7: 7.6 µg apo E alone. Image on right
is the same gel stained with CBB.

Sequence comparison analysis
Highlighting group-related amino acids in sequence files
discussed in Methods revealed the location of clusters and
motifs that were then used to align multiple sequences.
Region 1, the N-terminal sequence of apo B100
Capsid proteins of the flaviviruses and DNA binding domains of irf proteins are rich in arginine and lysine amino
acids. Arg/Lys-rich clusters are located near the N-termini
of apo B100, hcv, ylfv, dng 1–4, and irf proteins 1, 2, 5, 6, 8,
and 9. In the sequences of irf proteins 3, 4, and 7 and wnlv
and bvdv, Arg/Lys clusters are located distal to the first 20
N-terminal residues.
Flaviviruses are thought to gain cell entry via the LDL B/E
receptor (24, 25). The well-established B/E receptor ligand
region in apo E is an Arg/Lys-rich cluster, 0141LRKLRK0146
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quences containing these features were then aligned and grouprelated amino acids in multiple sequences were highlighted to
further assess similarity. Two regions in the apo B100 sequence
were selected for these analyses: Region 1 spans the N-terminus
from Glu0013 to Pro0140 and Region 2 includes residues Asp3313 to
Arg3500. Each of these apo B100 regions contains at least one
basic amino acid cluster. Different options for multiple sequence
alignment were also evaluated using T-COFFEE (http://www.
bioinformatics.nl/tools/t_coffee.html).
Sequence comparison was also performed using two recognized algorithms for sequence similarity searches, SSEARCH and
PSI-BLAST. The entire sequences of Regions 1 and 2 of apo
B100, as well as their fragments and expanded versions, were
used as query sequences. SSEARCH of UniProtein Knowledgebase, and UniProtKB/SwissProt databases was performed at the
EBI site (http://www.edi.ac.uk/Tools/fasta33/index.html) using all available BLOSUM matrices (BLOSUM 50, 62, and 80)
and default or weaker gap penalties (e.g., BLOSUM 62 has -11/-1
for gap opening/gap extension as default setting). PSI-BLAST
searches were conducted at the NCBI website (http://blast.
nchi.nlm.nih.gov/Blast.cgi). Databases of various sizes were
searched, each with various search settings such as scoring matrices
(BLOSUM 45, 62, and 80) and PSI-BLAST thresholds. Several
iteration steps (3–5 times) were performed until the search did
not result in any new additional finds.

Apo E similarity to Flaviviridae capsid proteins
A sequence alignment comparison of the apo E sequence containing the B/E receptor ligand, residues
Leu151 to Arg278, and the sequences of the four versions of
dng was performed to identify analog elements. Results are
presented in Table 2. The dng1 and dng3 proteins have
three discrete Arg/Lys-rich cluster in their N termini, each
containing a copy of the K/R-XX-K/R motif (underlined
in columns 1 and 2). Additional analog sequences are
highlighted in bold in column 2. A potential bipartite NLS
sequence was identified in the carboxy-terminal region of
the apo E molecule (column 3, Table 2).
In summary, the N-terminal region of apo B100, the
LDL B/E receptor ligand region of apo E, capsid proteins of the several flaviviruses, and the DNA binding
domain regions of the irf proteins appear to be analogs
of each other, which suggests similar functions. For
apolipoproteins, these similarities mean potential DNAbinding and nuclear translocation capacities. In turn,
similarity of Flaviviridae capsid proteins to apolipoproteins may greatly facilitate ability of these viruses to penetrate cells.
Region 2, the putative helicase domain of apo B100
The apo B100 sequence extending from Asp3313 to Ser3458
was predicted to bind DNA and mediate cell entry due
to the presence of both Arg/Lys-rich clusters and the accepted B/E receptor ligand sequence, 3353KLEGTTRLTRKRGLKLA3369. Based on the apparent preferential
binding of LDL to plasmids containing the HCMV IE2 promoter (20), this region of the apo B100 sequence was compared with the sequence of the HSV5 UL122 protein, which
binds to the CMV promoter (36). The apo B100 Region 2
sequence was also compared with the NS3 helicase of the
Flaviviridae viruses, dng1, wnlv, and ylfv, because an Arg/
Lys-rich cluster was located within the NS3 sequence by
highlighting of the arginine and lysine residues in their
precursor polyprotein sequences. The sequence alignment
comparison of the NS3 helicase domains of the HSV5
UL122 and Flaviviridae NS3 to the proposed analog sequence in apo B100 is presented in Table 3. Apo B100 (residues 3316–3458) and UL122 (residues 276–420) share
motifs KSS, LLSSSSSV, and GTTR. In column 3, a comparison of arginine/lysine-rich clusters of the NS3 helicases,
e.g., 1685REAIKRKLRT in dng1, and the analog sequence in
apo B100 LDL B/E receptor ligand, 3359RLTRKRGLK, is
shown. In the NS3 helicases of dng, wnlv, and ylfv, the KXXR
motif is part of the Walker A motif (34, 46), GXGKTRR.
Analog sequences occur as GTTRLTR in apo B100 and as
ASTGPRKKK in UL122 (Walker motifs are associated with
nucleotide binding in kinases and helicases) (47). Flanking
the Walker A motifs in the viral helicases are sequences of
two ␤-sheet structures, e.g., QITVLDL and LRTAVLAP in
wnlv. These are conserved in analog sequences SSSVIDA
and LKLATALS in apo B100. The hydrophobic stretch,
3367
KLATALSLSNKFV, which follows the receptor ligand
in apo B100, may be a legitimate analog to the sequence
1691
KLRTLILAPTRVV in dng1 and other Flaviviridae helicases (35). The sequence alignments in columns 4 and 5
Apo B100 similarities to viral proteins
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(27). The critical residues in binding/docking to the
receptor are lysine residues 0143 and 0146, which are
located on the hydrophilic side of an amphipathic helix
(27). Replacing either lysine with arginine (as RXXK or
KXXR) does not affect binding affinity; however, arginine
substitution of both sites (RXXR) reduces binding by
almost 70% (27).
The R/K-X-X-R/K is a multi-functional motif (including RXXR) essential in both protein-protein interactions,
including nuclear entry (NLS sequences) and proteinnucleic acid interactions (40–43). A comparison of the R/K
clusters in Region 1 of apo B100, flaviviral capsid proteins,
and irf DNA binding domains is shown in Table 1. The
N-terminal cluster of apo B100 contains three renditions
of the R/K-XX-R/K motif as RXXH, KXXR, and HXXK
(see column 1); apo E N-terminus has HXXK, two RXXR,
and one KXXK; there are three copies in hcv (KPQR,
RKTK, KTKR); one as RXXR in ylfv; and all versions of
Dengue capsid proteins are replete with this motif, bipartite NLS sequences, and the R/K-X-R/K-X-R/K motif.
Arginine, in RXRXR and RXXR motifs, is the predominant basic amino acid in the N-terminal clusters of the irf
proteins. Only the RXXR low affinity B/E receptor ligand
motif is present in the N-termini of DNA binding domains
of irfs 5, 6, 8, and 9. The high-affinity B/E receptor ligand
motifs (27) KXXK, KXXR, and RXXK, absent in the
N-terminal R/K clusters of irf proteins, are present in their
DNA binding and NLS motifs located in the C-terminal
region of these domains (44).
The motif K/R-XXX-K/R shown in column 3 and present in the sequences of apo B100 Region 1, bvdv, hcv, and
irfs is repeated several fold in the irf proteins. Another motif that appears in most of these proteins is the ⌽ ⌽ ⌽-K/R
motif (⌽, hydrophobic residue); it is also highlighted in
column 3. In irfs, these motifs have been shown to interact
with the backbone phosphate moieties of the nucleic acid
(45).
Analogs of the K/R-XXX-K/R motif, shown in column
4, are part of the NLS sequence located before the metalbinding sequence of the irf proteins (45). The apo B100
sequence, NPEGKALLK is very similar to the sequence
QPEGRAWAQ in hcv capsid protein. In irfs, the NPEG appears as EPDP and is separated from the K/R-XXX-K/R
motif by a tripeptide sequence, KTW, missing in apo B100,
and two viral capsid proteins, bvdv and hcv. An analog of
the apo B100 sequence, KKTKNSEEF, is contained in the
bvdv as TKSKNTQDG and as “NKSSEF” in irf 9.
A PG motif is also located near the N termini of apo
B100, hcv, and irf proteins 1, 2, 4, 5, 6, 8, and 9 but not 3
and 7 (column 2, Fig. 1). The PG motif was used as a reference point for alignment and served in locating clusters of
polar amino acids, also highlighted in column 2.
In hcv, the capsid/core protein is cleaved within a short
0175
0183
stretch of hydrophobic amino acids, SIFLLALLS (26).
Analog sequences are also present in other flaviviruses.
Three motifs contained in this region of the hcv capsid protein, shown in column 5, are also apparent in apo B100,
0132
GIISALLVP0140 (with 2 potential cleavage sites), 0148QV0152
0158
NCS0160 (a potential N-glycosylation site).
LFL , and
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proteins included in Tables 1 and 3, and these resulted in
the detection of viral sequences only.
LDL-mediated transfection of cells in culture
Different cell types, including HeLa, Hep G2, CHO, and
NIH3T3, were transfected using LDL mixed with BOBO-1labeled plasmid DNA containing the HCMV promoter as
described in Methods. Typically, LDL-mediated transfection
of HeLa, Hep G2, and NIH3T3 cells occurred rapidly after
upregulation of the B/E-receptor via incubation of cells in
FBS-free medium for 2–4 h; fluorescence was observed within
minutes after LDL/BOBO-1-DNA mix is added to the medium. Almost 100% of HeLa cells shown in Fig. 2A were
transfected within 30–45 min, and BOBO-1 fluorescence is
seen predominantly in cell nuclei. In CHO cells, transfection
occurred over an extended period for hours, not minutes
(Fig. 2B). Also, fluorescence appeared to remain in the
cytoplasm with little to none in nuclei. Few to no cells were
transfected in all cell types by naked DNA (Fig. 2C).
In Hep G2 cells, two fluorescence dyes (CM-DiI for
transfection agents, BOBO-1 for pCMV ␤-Gal DNA) were
used to compare Lipofectin- and LDL-mediated transfection (Fig. 2D–K). All images were taken at 3 h after transfection. This time point was chosen for optimal transfection
results using Lipofectin, which was delayed compared with
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weakly suggest similarities between these proteins. Notably,
the DEAD motif typical of helicases is not conserved in apo
B100 but may be represented as DFNS.
Our method for sequence comparison analysis identifies weakly similar sequences that may be analogs of known
proteins and therefore may perform similar functions.
This algorithm reveals that apo B100 Region 1 sequence
shares about 46% similarity and 22% identity with the DNA
binding domains of the irf proteins and about 25% similarity and <10% identity with the viral capsid proteins. Sequence similarities between apo E and the irf proteins
were <25%. The apo E sequence spanning 0155Leu and
0248
Asp is 55% similar to the first 100 N-terminal residues of dng1.
Similarity searches using SSEARCH and PSI-BLAST algorithms were performed to probe the protein sequence
databases for potential homologies and to further substantiate our observations. Although these algorithms find several matches to RNA- and DNA-binding proteins in the
SwissProtein database, the E-value range for these matches
is 1 < E < 10 and is therefore not considered highly significant. All statistically significant homologs belong to several
families of lipoprotein transport proteins of animals,
and no significant viral homologs were revealed. Similar
searches were performed with input sequences of the viral

these experiments. Fluorescence was not seen in controls
where naked DNA was used (not included). Merged overlays of brightlight and fluorescence images in Fig. 2L
show GFP expression in MCF7 cells at 2 h after transfection. Loci of apparent GFP synthesis are visible on the
periphery of nuclei. GFP expression was seen in <10%
CHO cells examined (Fig. 2M). Intense and uniform
distribution of GFP expression was seen in NIH/3T3 cells
at 18 h (Fig. 2N) and in HeLa cells at 1 h (Fig. 2O) and
18 h (Fig. 2P) post transfection. Nuclei devoid of GFP
are clearly visible (Fig. 2P). In summary, images in Fig. 2
unambiguously demonstrate successful LDL-mediated
intracellular delivery and nuclear translocation of dyelabeled DNA as well as GFP expression in transfected
cells in vitro.
Animal studies
Rats inoculated with rat or human LDL/pEGFP-N1 mixtures via multiple ports were euthanized on days 2, 5, and
7 (Methods). However, GFP expression was not observed
in tissues harvested on days 5 and 7. Photographs taken

Apo B100 similarities to viral proteins
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LDL-mediated DNA delivery. Uptake of label was not seen
in cells given DNA only (not shown). Extracellular location of fluorescence can be seen in cells treated with labeled Lipofectin alone (Fig. 2D). These extracellular
aggregates may result from Lipofectin interaction with cell
debris or may form before its cell entry. In contrast, signal
from labeled LDL is typically seen associated with cells
(Fig. 2H). Micrographs E–G and I–K illustrate cellular uptake of dual labeled Lipofectin/DNA and LDL/DNA
complexes, respectively. Red fluorescence of labeled Lipofectin (Fig. 2E) in the cytoplasm is more intense and not
in discrete loci as seen for labeled LDL (Fig. 2I). Little or no
red fluorescence is present in the nuclear spaces. BOBO-1
green fluorescence is seen in nuclei and cytoplasm of cells
transfected with Lipofectin/DNA (Fig. 2F) and LDL/DNA
(Fig. 2J). Dual color images (Fig. 2G, K) further emphasize colocation and separation of dyes suggested by the
monochrome images.
LDL-mediated delivery of pEGFP-N1 DNA to cells was
tested further by monitoring GFP expression in different
cell types (Fig. 2, right panel, L–P). No dyes were used in
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Fig. 2. LDL-mediated transfection of mammalian cell types with plasmid DNA containing HCMV promoter. Upper-left panel: Images
A–C: LDL-mediated transfection of HeLa (A) and CHO cells (B) with BOBO-1-labeled pCMVTNT. HeLa cells given labeled plasmid
alone are in C. Lower-left panel: Images D–K: HepG2 cells transfected using Lipofectin (D–G) and LDL (H–K) in dual label experiment.
BOBO-1-labeled, linearized pCMV ␤-Gal combined with CM-DiI-labeled transfection agent was given toHepG2 cells (Methods). Images
D (Lipofectin) and H (LDL) are brightlight and FITC filter overlay (merged) images of HepG2 cells treated with CM-DiI-labeled transfection agent alone. Images E–G show cells incubated with CM-DiI-Lipofectin/BOBO-1-pCMV␤-Gal, and images I–K show cells treated
with CM-DiI-LDL/BOBO-1-pCMV ␤-Gal. Images E (Lipofectin) and I (LDL) obtained with the FITC filter show location of labeled
transfection agents only. Images F (Lipofectin) and J (LDL) obtained using the GFP filter cube show labeled-DNA loci. Images G and K
are merged images (D/E, Lipofectin) and (I/J, LDL) that show coloci and separate loci of labeled transfection agents and DNA. Right
panel: Images L–P: GFP was expressed in a variety of cell types after LDL-mediated transfection with pEGFP-N1 plasmid DNA. Images
are merged overlays of brightlight and fluorescence micrographs. L: MCF7, and M: CHO cells at 2 h after transfection. N: NIH/3T3 cells
at 18 h after transfection. O, P: HeLa cells at 1 h (O) and 18 h (P) post transfection. GFP expression appears as pronounced green
fluorescence.
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Synthetic peptide studies
Synthetic peptides of apo B100 Regions 1 and 2, presented in Tables 1 and 3, were obtained to evaluate the
role of apo B100 in nucleic acid-binding, transport, and
delivery. Two additional criteria were important in selecting these regions: presence of an apo E receptor ligand
analog sequence and solubility (hydrophilicity and hydrophobicity), based on ratio of charged and polar amino

acids to nonpolar, hydrophobic amino acids (4). The N
terminus, residues 0012 thru 0160 (Region 1), and the
known B/E receptor ligand region, residues 3313Asp thru
Ser3458 (Region 2), meet these criteria.
In EMSA studies, synthetic peptides B1-1 (0014Lys-Glu0054)
and B1-2 (0055Leu-Ala0096) were shown to bind phMGFP
DNA in the presence of 10 mM MgCl2 (Fig. 4). Electrophoresis was performed in a 0.8% agarose and TA buffer.
Results are shown in image A: for plasmid only, lane 1;
plasmid plus 3, 6, and 12 µg of each peptide, B1-1 (0014LysGlu0054), lanes 2, 3, and 4, respectively; B1-2 (0055LeuAla0096), lanes 5–7; B2-1 (3313Asp-Glu3355), lanes 8–10; B2-2
(3356Gly-Thr3431), lanes 11–13; B1-1/B1-2 (R1) mix, 8 µg
each, lane 14; and B2-1/B2-2 (R2) mix, 8 µg each, lane 15.
Peptides visualized with Coomassie Blue dye in the gel
are in image B. Results for peptide B2-3 (3358Thr-Leu3373), the
known B/E receptor ligand, mixed with plasmid are shown
in image C, DNA alone (lane 16), and DNA plus 10 µg
peptide (lane 17).
Cocktails of B1-1/B1-2, Region 1, mixed with phMGFP
were shown to deliver BOBO-1-labeled DNA to preconditioned HeLa cells within 1 h after addition of peptides/
DNA complex to the medium (Fig. 5A–H). As time progressed, fluorescent, amorphous cell debris was observed.
Cell experiments using peptides alone confirmed the cytotoxicity of Region 1 peptides (Fig. 5I, J), as indicated by
the accumulation of Trypan blue dye in the cell culture
treated with these peptides.
Synthetic peptides B2-1 (3313Asp-Glu3355), B2-2 (3356GlyThr3401), and B2-3 (3358Thr- Leu3373) were also shown to
bind phMGFP DNA in the presence of 10 mM MgCl2 (Fig.
4). Binding of the B2-3 peptide appeared to be weak, resulting only in a smearing appearance of the plasmid band.
Cocktails containing peptides B2-2 and B2-3 with DNA
were ineffective in transfecting HeLa cells (results not included). Further, these peptides were shown to be noncytotoxic (Fig. 5K, L).

DISCUSSION
LDL and VLDL transport lipids in the plasma and are
characterized by apo B100 as their major protein. We have
demonstrated plasmid DNA-binding capacity for these lipoproteins and that DNA bound to LDL is transferred to
the cell nucleus. Our results confirm that LDL is an effective transfection vector in vivo and in vitro. Lp (a), another
apo B 100-containing particle that may be present in small
quantities in the LDL fraction with buoyant density < 1.050
g/ml (48), was not shown to possess DNA-binding capacity
(20). Apo (a), the massive, hydrophilic molecule covalently linked and noncovalently attached to apo B100 to
form Lp (a), contains only one Arg/Lys-rich cluster in the
kringle domain in the single copy of kringle type 11 and
two in the putative serine protease domain (49, 50). Kringle types 1–10 in apo (a) are similar to plasminogen kringle 4 (49) and are devoid of basic amino acid clusters and
motifs suggestive of nucleic acid binding or nuclear translocation. The noncovalent interactions between apo (a)
Apo B100 similarities to viral proteins

1713

Downloaded from www.jlr.org by guest, on January 22, 2020

immediately after collection of tissue sections on day 2 are
shown in Fig. 3. In the top row, GFP fluorescence is seen
in the basal cell layer of the stratified squamous epithelium of the esophagus (Fig. 3A). No fluorescence is visible
in the lamina propria region located at the lower portion
of the image. GPF fluorescence is also seen in the spinal
cord (Fig. 3C), lung (Fig. 3E), liver (Fig. 3G), and heart
(Fig. 3I) in animals given rat LDL/pEGFP-N1 plasmid
cocktail. Fluorescence was not detected in samples from
both large and small intestine, brain, and dorsal aorta (images not included). The intense fluorescence seen in the
spiral and tubular structures in the lung image (Fig. 3E)
and the endothelium of the hepatic vein (Fig. 3G) was a
matter of concern, because these structures are characterized by elastic laminae, which are known to autofluoresce.
However, images of tissues obtained from control animals
treated only with the HindIII-cut pEGFP-N1 (Fig. 3B,
esophagus; D, brain; F, lung; H, liver; J, heart) showed no
or low intensity fluorescence. In the rat inoculated with
human LDL/pEGFP-N1 complex, intense fluorescence is
visible in the myocardial tissue (Fig. 3K). Results obtained
from other tissues from this animal were inconclusive.
Separate experiments were conducted to compare
tissue distribution of the luciferase gene delivered as
pGL2-Control DNA alone or complexed to LDL, cationic
liposome, or to a mixture of LDL and liposome. Each rat
was given one injection of DNA/transfection agent mix at
a single site (see Methods). DNA extracted from each tissue was analyzed by PCR using luciferase-specific primers
(Fig. 3, lower panel). A qualitative comparison of these results is shown in Table 4. Briefly, pGL2-Control vector
alone appears to transfect liver, brain, and spleen at barely
detectable levels. Whether the DNA binds to LDL particles
present in the rat’s plasma was not determined in these
studies. LDL-mediated delivery was highly effective in the
kidney and spleen, somewhat effective in brain and heart,
but negative results are seen in the lungs and liver. The
difference between results obtained in LDL-mediated
transfection with GFP gene and the luciferase gene, both
driven by the CMV promoter, may be attributed to different
inoculation methods (multiple sites of inoculation/application in the former study vs. single site injection in the latter
experiment). The liposome-plasmid complex was highly effective in liver and visibly effective in heart, transfected lung,
kidney, and spleen at lower levels, but was negative in brain.
The LDL/Liposome mix was highly effective in delivery of
the plasmid to the heart and lung, less effective in spleen,
only slightly effective in brain, and negative in liver and kidney. These preliminary results confirm that LDL particles
are useful transfection vectors in vivo.

and apo B100 that probably involve lysine residues on the
apo B100 (50) may render nucleic acid binding regions
inaccessible. Hence, the Lp (a) particle may not have a
role in the transport and delivery of nucleic acids.
LDL transfection capacity is likely based on apo B100,
which provides the particle with DNA binding and cell entry potential. Sequence similarities in apo B100, apo E,
TABLE 4.
Tissue

Heart
Liver
Lung
Brain
Kidney
Spleen
Esophagus
Spinal Cord

and known nucleic acid-binding domains of transcriptional
regulators (irf proteins and capsid/core proteins of Flaviviruses) provide an explanation for the capacity of LDL to
bind DNA and RNA (17–23). These sequence similarities
and experimental results strongly suggest that the first 160
residue N-terminal region of apo B100 and LDL receptor
ligand region of apo E have functions of nucleic acid bind-

Post-transfection distribution of the reporter genes in rat tissues

pGL2 Plasmid
only

LDL/pGL2
Complex

Liposome/pGL2
complex

LDL/liposome/ pGL2
complex

LDL/pEGFP-N1
complex*

Negative
Slightly positive
Negative
Slightly positive
Negative
Slightly positive
Not assayed
Not assayed

Positive
Negative
Negative
Positive
Highly positive
Highly positive
Not assayed
Not assayed

Positive
Highly positive
Slightly positive
Negative
Slightly positive
Slightly positive
Not assayed
Not assayed

Highly positive
Negative
Highly positive
Slightly positive
Negative
Positive
Not assayed
Not assayed

Highly positive
Highly positive
Highly positive
Negative
Not examined
Not examined
Positive
Positive

Rats were transfected in vivo with pGL2-Control plasmid, alone (column 2) or complexed to LDL (column 3),
liposome (column 4), or to LDL/liposome mix (column 5). Presence of luciferase gene was determined by PCR in
heart, liver, lung, brain, kidney, and spleen tissues (column 1) of the rat on day 2 after transfection. GFP expression
in tissues of the rat transfected with pEGFP-N1 plasmid/LDL mix (column 6) was determined on day 2 and was
based on green fluorescence in frozen section of different tissues. The data are illustrated in Fig. 3. * Inoculant was
administered at multiple sites.
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Fig. 3. GFP expression and tissue distribution in rat. Top panel: GFP was expressed in esophagus (A, basal cells of stratified squamous epithelium), spinal cord (C), lung (E), liver (G), and heart (I, rat LDL-mediated transfection, and K, human LDL-mediated transfection).
Frozen sections (4–8 µm thick) were obtained 2 days after the animals were given a mixture of LDL and linearized pEGFP-N1 DNA (images
A, E, I, C, G, K) via multiple ports as described in Methods. GFP expression is not seen in control animals given interrupted plasmid DNA
alone (B, D, F, H, J, L). Bottom panel: Distribution of luciferase gene in rat tissues. Lanes 1–6 show luciferase-specific 800 bp band in heart,
liver, lung, brain, kidney, and spleen, respectively. Rats were transfected using pGL2-Control plasmid alone, or cocktails of rat LDL/pGL2Control, Liposome/pGL2-control, and rat LDL/Liposome/pGL2-Control plasmid. DNA was extracted from rat tissues on day 2 after
transfection and assayed using PCR with luciferase-specific primers 5′agcaactgcataaggctatg and 3′gttggtactagcaacgcact.

Fig. 4. EMSA of Apo B100-derived peptides and
phMGFP. Sample cocktails were prepared using 0.42
µg of phMGFP plasmid and increasing quantities of
0014
0096
each peptide derived from Region 1 ( Lys-Ala )
3313
3431
and Region 2 ( Asp-Thr ) of apo B100, as well as
combinations of peptides derived from the same region. Amino acid sequences of the peptides are listed
in Table 2 (Region 1) and Table 3 (Region 2). Electrophoresis was performed in a 0.8% agarose and TA
buffer. A: lane 1: plasmid only; lanes 2, 3, and 4: plasmid plus 3, 6, and 12 µg, respectively, of peptide B1-1
(0014Lys-Glu0054); lanes 5, 6, and 7: plasmid plus 3, 6,
0055
and 12 µg, respectively, of peptide B1-2 ( Leu0096
Ala ); lanes 8, 9, and 10: plasmid plus 3, 6, and 12
3313
3355
µg, respectively, of the peptide B2-1 ( Asp-Glu );
lanes 11, 12, and 13: plasmid plus 3, 6, and 12 µg,
3356
3431
respectively, of peptide B2-2 ( Gly-Thr ); lane
14: plasmid plus B1-1/B1-2 (R1) mix, 8 µg each; lane
15: plasmid plus B2-1/B2-2 (R2) mix, 8 µg each. B:
pCMVTNT DNA, 1 µg alone (lane 16) and mixed
3358
3373
with peptide B2-3 ( Thr-Leu ), 10 µg (lane 17).
C: Same gel, lanes 1–15, stained with CBB.

regulate transcription (52–55). In the flaviviruses, once
the polyprotein is expressed, the capsid proteins are
cleaved by an endopeptidase at one of two dipeptide motifs of small hydrophobic amino acids such as Leu-Leu
(26). Analogs of these dipeptide motifs are also present in
a like-region of apo B100 as Ile-Ile and Leu-Leu. It is interesting to consider a similar mechanism is employed to
release the N-terminal region of apo B100 for similar
functions. Another property reported for the wnlv capsid/
core protein is cytotoxicity (52, 56–58). This effect was also
observed with the B1-1/B1-2 peptides mix on HeLa cells.
One possible scenario would be that the N-terminal region
of apo B100 is cleaved so that it may compete with viral
capsid proteins for the nucleic acid and/or kill infected
cells to suppress the infection process.
The synthetic peptides of the apo B100 region 2 were
shown to bind DNA in EMSA. Region 2 sequence is similar
to HSV5 UL122 helicase and Flaviviridae NS3 helicases and
contains several analog motifs present in these viral proteins. Surprisingly, these peptides were ineffective in delivery of DNA to the cells despite the presence of the know
B,E-receptor-binding ligand, possibly due to blocking of
the receptor ligand site by DNA or inadequate conformation for docking with the receptor.
In summary, apo B100 and apo E, constituent proteins in LDL and VLDL, share many similarities with the
flaviviral proteins that may be construed as analogs. Significant viral homologs were not found in the databases
using recognized search algorithms and therefore lessen
the possibility that these apolipoproteins are viral in origin. These apolipoproteins may have evolved as part of
the immune system to address and/or eliminate viral
(microbial) nucleic acids from circulation. Alternatively, we can consider also that flaviviruses may have
evolved to mimic apo B100 and apo E domains to gain
cell entry and evade the immune system of the host.
Viral genomes are known to evolve faster than the
Apo B100 similarities to viral proteins
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ing. Synthetic peptides covering part of this apo B100
region, Region 1, bind plasmid DNA and substantiate this
function to a degree, with the caveat that ligand specificity
and peptide conformation are undetermined. Region 1
peptides also mediate cell entry for plasmid DNA, presumably via the B/E receptor and/or through the mechanism(s)
used by Arg/Lys-rich cell-penetrating peptides (51). NLS
sequence motifs are characterized by Arg/Lys-rich clusters,
as in the DNA binding domains of most irf proteins and in
the capsid/core proteins of hcv and other Flaviviridae viruses. Hence, apo B100 Region 1 contains motifs that impart nucleic acid binding, mediate cell uptake, and are
apparently involved in transferring DNA into the cell
nucleus.
Several studies suggest that Flaviviridae viruses may gain
cell entry via the B/E receptor (24–26, 52). This mechanism is thought to involve the E1 and E2 structural proteins of the virus (26). Although one LRK motif occurs in
envelope proteins of dng1 and dng3, our examination of
the primary structures of dng1 envelope proteins did not
reveal a complete apo E receptor ligand Arg/Lys-rich cluster similar to those contained in its capsid protein. However, four additional analogs of the K/R-XX-K/R are
contained within the sequence spanning 0561Gly to 0695Leu
of the dng1 polyprotein sequence. In hcv and the four versions of dng, Arg/Lys-rich clusters containing multiple
copies of the K/R-XX-K/R motif similar to those in the
apo E receptor ligand sequence are located near the N
termini of the capsid proteins. In wnlv and ylfv, the motifs
are also located in the capsid proteins but are distal to the
N terminus. It is therefore possible that cell entry is mediated by capsid proteins as well, and the almost ubiquitously
expressed LDL B/E receptor may enhance viral infectivity
and viability.
Flaviviral capsid proteins are multi-functional proteins,
i.e., they bind nucleic acids, translocate nucleic acids to
cell nucleus, have a role in dimerization of viral RNA, and

human genome. This ability paired with typically large
population sizes can result in a fast selection of viral
protein patterns that are able to mimic LDL receptorbinding motifs.
We surmise that the transport of nucleic acids by LDL
may occur naturally and may be an essential function. Lipids may mediate the conformation state of the apo B100 for
addressing a wide spectrum of nucleic acids as well as interactions with proteins. A function of apo B100- and apo
E-containing particles may be in removing viral or other
microbial nucleic acid debris from circulation. It is interest1716
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ing to speculate that LDL may be also binding in vivo to
circulating nucleic acids in plasma, which are present under
normal conditions and are elevated in several diseases including acute inflammation and cancer (59–62). The role
played by LDL and VLDL in the dissemination of hcv genomic RNA has been established by other investigators (16,
17, 19), and binding of LDL to genomic DNA was reported
previously (18, 20, 23). Combined with the capacity of LDL
to transfect different cell types and tissues, these observations suggest that perhaps LDL, and possibly VLDL, play a
similar role in the mechanisms of metastatic disease.
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Fig. 5. Synthetic peptide mediated transfection of HeLa cells. Top panel: Synthetic peptide mediated
transfection of HeLa cells with BOBO-1-labeled phMGFP plasmid. Dye-labeled plasmid DNA complexed to
apo B100-derived peptides was used to transfect HeLa cells grown in DMEM medium as described in Methods. All frames show a merged overlay image of the fluorescence micrograph and the corresponding phase
contrast version. Frames A thru C show cells transfected using cocktails of synthetic peptides B1-1 and B1-2
(Table 2) derived from N-terminal region of Apo B100 mixed with 1.0 g BOBO-1-labeled phMGFP plasmid
DNA: A: 1.5 nmol of B1-1 and 1.9 nmol of B1-2 plus plasmid; B: 5.9 nmol of B1-1 and 7.5 nmol of B1-2 plus
labeled plasmid; C: 15 nmol of B1-1 and 19 nmol of B1-2 plus labeled plasmid. All transfection experiments
were conducted in 400 l of DMEM. Enlarged cut-out images in inserts D–H show intracellular loci of label.
All images were obtained using a Zeiss Axiovert 25 scope and the Optronics MicroFire CCD camera. Bottom
panel: Cytotoxic effects of peptides B1-1 and B1-2 on HeLa cells are demonstrated using Trypan Blue dye.
Cytotoxicity caused by mixtures of synthetic peptides B1-1 and B1-2, 4 µg each peptide (frame I) and 10 µg
each peptide (frame J), added to preconditioned HeLa cells in DMEM. In contrast, no cytotoxicity is seen
for HeLa cells treated similarly with mixtures containing the same quantities of synthetic peptides B2-1/
B2-2, frames K and L, respectively.

These studies offer a new perspective in our understanding of the pathogenic nature of apo B100 lipoproteins.
Changes in lipid content, chemical modifications of apo
B100, accumulation of lipo-viral debris, and other changes
affecting nucleic acid-binding capacity of LDL may alter
functionality of these particles.
LDL and peptides derived from the apo B100 have great
potential as nucleic acid transport and delivery vehicles
with applications in gene replacement therapies, DNA vaccines, rapid creation of transgenic animals, and cell bioreactors in the production of pharmaceutical proteins. LDL
and VLDL are the only delivery nanoparticles that can be
used in autologous formulations. Unlike viral or synthetic
vectors and cell penetrating peptides (63), autologous
LDL will not elicit an immune response. LDLs are easily
purified and can be readily stored for long periods in liquid nitrogen. These naturally occurring particles can be
exploited in the development of accurate gene replacement formulations.
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